Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ASP5354 in Healthy Japanese Men
NCT04878471Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2021
- Primary completion
- Jul 2021
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in iatrogenic ureteral injury comparing ASP5354 with Matching Placebo (2 arms). Primary endpoints: Number of participants with Adverse Events up to 6 days, Number of participants with laboratory value abnormalities and/or adverse events up to 6 days and 2 more. Started Jun 2021; status: completed.
02
Drugs
pudexacianinium chloride
03
Conditions
iatrogenic ureteral injury
Beyond the preview
Go deeper on NCT04878471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04878471.